Core Insights - NeurAxis, Inc. reported preliminary, unaudited revenues for Q4 2024 of approximately 2.7 million, an 11% increase from FY 2023 [1][6] Revenue Growth - The company experienced a significant revenue growth acceleration in Q4 2024, with a 50% increase compared to 40% growth in Q3 2024 [2] - The strong revenue growth in the second half of 2024 was attributed to expanded insurance coverage, which now supports approximately 45 million lives, up from 4 million a year ago [2] Future Outlook - NeurAxis expects continued robust revenue growth in 2025 and beyond, driven by expanding insurance coverage policies and recent FDA 510(k) clearance for IB-Stim, which now includes patients aged 8 to 21 years [3] - The company plans to commercialize its Rectal Expulsion Device (RED) in Q1 2025, following FDA approval [3] Financial Position - As of December 31, 2024, NeurAxis had a cash balance of approximately $3.7 million, positioning the company to achieve near-term growth objectives and reach cash flow breakeven [4][6]
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year